Across TCGA pan-cancer cohorts, RNASEK mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RNASEK data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNASEK mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RNASEK expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

OV are the cancer types where RNASEK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.982	0.821	.033	8	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RNASEK tumor-vs-normal RNA expression · all RNASEK data types